Usefulness of Sofia Pneumococcal FIA® test in comparison with BinaxNOW® Pneumococcal test in urine samples for the diagnosis of pneumococcal pneumonia
The Sofia Pneumococcal FIA® test is a recently introduced immunofluorescent assay automatically read aimed to detect Streptococcus pneumoniae antigen in urine. The aim of this study was to evaluate the usefulness of SofiaFIA® urinary antigen test (UAT) in comparison with classical immunochromatographic BinaxNOW® test for the diagnosis of pneumococcal pneumonia (PP). Observational study was conducted in the Hospital Universitari Vall d’Hebron from December 2015 to August 2016. Consecutive adult patients diagnosed of pneumonia and admitted to the emergency department in whom UAT was requested were prospectively enrolled. Paired pneumococcal UAT was performed (BinaxNOW® and SofiaFIA®) in urine samples. To assess the performance of both tests, patients were categorized into proven PP (isolation of S. pneumoniae in sterile fluid) or probable PP (isolation of S. pneumoniae in respiratory secretion). Sensitivity, specificity, and concordance were calculated. A total of 219 patients with pneumonia were enrolled, of whom 14% had a proven or probable PP, 22% a non-pneumococcal etiology, and 64% an unidentified pathogen. Concordance between tests was good (κ = 0.81). Sensitivity of SofiaFIA® and BinaxNOW® UAT was 78.6 and 50% for proven PP (p = 0.124), and 74.2 and 58% for proven/probable PP (p = 0.063). Specificity for both tests was 83.3 and 85.5% for proven and proven/probable PP. In patients without an identified pathogen, SofiaFIA® test was positive in 33 (23.6%) cases and BinaxNOW® in 25 (17.8%), so Sofia Pneumococcal FIA® detected 32.6% more cases than BinaxNOW® (p = 0.001). Sofia Pneumococcal FIA® test showed an improved sensitivity over visual reading of BinaxNOW® test without a noticeable loss of specificity.
KeywordsPneumococcal urinary antigen test Sofia Pneumococcal FIA® test BinaxNOW® Pneumococcal test Community-acquired pneumonia
Compliance with ethical standards
Conflict of interest statement
The authors declare that they have no conflicts of interest.
The study was approved by the Ethics Board of the hospital (Ethics Committee of Clinical Investigation [Hospital Vall d’Hebron. PR(AG)368/2015]).
Informed consent was waived due to the observational nature of the study.
- 5.Genne D, Siegrist HH, Lienhard R (2006) Enhancing the etiologic diagnosis of community-acquired pneumonia in adults using the urinary antigen assay (Binax NOW). J Infect Dis 10:124–128Google Scholar
- 8.Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Jr, Musher DM, Niederman MS, Torres A, Whitney CG. 2007. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2):S27–S72Google Scholar
- 14.European Centre for Disease Prevention and Control. European Legionnaires’ Disease Surveillance Network (ELDSNet): Operating procedures. Stockholm: ECDC; 2012Google Scholar
- 21.Congestrì F, Crepaldi E, Gagliardi M, Pedna MF, Sambri V (2016) Comparative evaluation of the novel bioNexia Legionella test with the BinaxNOW Legionella card assay and the Sofia Legionella FIA assay for detection of Legionella pneumophila (serogroup 1) antigen in urine samples. J Clin Microbiol 54:1164–1166CrossRefPubMedGoogle Scholar